When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CELG - Celgene's CC-486 successful in late-stage AML study
Celgene Corporation
A Phase 3 clinical trial, QUAZAR AML-001, evaluating Celgene's (NASDAQ:CELG) CC-486 (azacitidine) as maintenance therapy in newly diagnosed patients with acute myeloid leukemia (AML) who achieved first complete response (CR) or complete response with incomplete blood count recovery (CRi) with induction chemotherapy (with or without consolidation) met the primary endpoint of overall survival.
More news on: Celgene Corporation, Healthcare stocks news,